FDA Approves Mimrylo (Rusfertide): A Hepcidin-Mimetic Peptide for Polycythemia Vera

What the FDA approved—and what it did not

The FDA approved Mimrylo (rusfertide) on August 28, 2026 for the treatment of erythrocytosis in adults with polycythemia vera. That exact language is important. Polycythemia vera is a chronic myeloproliferative neoplasm in which excessive red-cell production raises hematocrit—the percentage of blood volume occupied by red blood cells. More viscous blood contributes to the disease's clinically important risk of arterial and venous thrombosis.

This was a full FDA drug approval of a specific manufactured prescription product, supported by an approved prescribing label. It was not an advisory vote, a compounding decision, or approval of hepcidin-like research products as a category. Mimrylo is also not approved for every cause of elevated hematocrit or for iron overload in general. Readers comparing regulatory categories can review FDA-approved peptides and the distinction between peptides, proteins, biologics, and small molecules.

The FDA described Mimrylo as the first approved PV treatment that mimics hepcidin. The regulatory milestone therefore has two dimensions: it adds an option for adults whose erythrocytosis has not been adequately controlled with existing care, and it validates a mechanism that controls the supply of iron to erythropoiesis rather than directly targeting the malignant clone that causes PV.

Why hepcidin biology fits polycythemia vera

Hepcidin is a peptide hormone made primarily by the liver and is the central systemic regulator of iron movement. Its key target is ferroportin, the iron-export protein on cells that release iron into plasma—especially intestinal enterocytes that absorb dietary iron and macrophages that recycle iron from aging red cells. When hepcidin binds ferroportin, ferroportin is internalized and degraded. Less iron then reaches circulating transferrin and the bone marrow.

That pathway matters because hemoglobin synthesis requires iron. In PV, a JAK2-driven marrow clone produces red cells too readily. Therapeutic phlebotomy lowers hematocrit by removing blood, but repeated blood removal also depletes iron stores. Iron restriction is not merely incidental: it helps constrain erythropoiesis, even as iron deficiency can add symptoms and practical burden. Simply replacing iron in a patient with active PV can stimulate further red-cell production, which is why iron decisions require hematology supervision.

Rusfertide is a synthetic cyclic disulfide peptide designed to reproduce hepcidin's functional signal. According to the FDA label, it blocks ferroportin and thereby reduces the iron available for red-cell production, lowering hematocrit. The label's pharmacodynamic data are consistent with that mechanism: after single doses in healthy participants, the largest serum-iron reduction occurred about 24–48 hours after dosing, with more sustained reduction at higher studied doses.

The pivotal VERIFY trial: who was studied and how

FDA based efficacy on VERIFY (NCT05210790), a multicenter, randomized, double-blind, placebo-controlled Phase 3 trial involving 293 adults with PV. Entry criteria selected a phlebotomy-dependent population with inadequate hematocrit control: participants needed at least three phlebotomies in the 28 weeks before randomization or at least five in the prior year while receiving ongoing standard care.

Participants continued background care and were randomized 1:1 to Mimrylo or placebo through Week 32. Background regimens included phlebotomy alone or phlebotomy with cytoreductive treatment. At randomization, 44.7% were receiving phlebotomy alone, 38.9% phlebotomy plus hydroxyurea, 13.3% phlebotomy plus interferon, 2.4% phlebotomy plus ruxolitinib, and 0.6% a combination of cytoreductive therapies. This design answers an add-on question: what benefit does rusfertide provide on top of the care these patients were already receiving?

Treatment began at 19 mg subcutaneously once weekly and was titrated to control and maintain hematocrit below 45%. The primary endpoint was response during Weeks 20–32, defined as the absence of phlebotomy eligibility. Eligibility meant either a confirmed hematocrit of at least 45% that was at least three absolute percentage points above baseline, or hematocrit of at least 48%. This is more precise than saying merely that a patient did or did not undergo a procedure: the endpoint used prespecified laboratory thresholds.

How to interpret the efficacy results

The primary result was large and statistically persuasive: 76.9% of Mimrylo-treated participants met the response definition during Weeks 20–32, compared with 32.9% on placebo. The absolute difference was 43.8 percentage points. Mimrylo also reduced the average number of phlebotomies over 32 weeks and increased the proportion maintaining hematocrit below 45%. These endpoints directly address a recurring clinical and logistical burden for the enrolled population.

The fatigue result points in the same direction but deserves proportionate wording. Fatigue was measured with the PROMIS Fatigue Short Form 8a, where higher scores mean worse fatigue. The between-group least-squares mean difference at Week 32 was −1.98 points. It was statistically significant in the prespecified analysis, but the label does not claim that every patient will experience a noticeable improvement. Patient-reported averages and individual benefit are not interchangeable.

VERIFY's controlled comparison lasted 32 weeks. Participants completing it could receive open-label Mimrylo through Week 52 and then enter long-term extension treatment. Those extensions add exposure and durability information, but once everyone knows or receives the active drug, they do not preserve the same randomized placebo comparison. The approval should therefore be read as strong evidence for hematocrit and phlebotomy-related efficacy in the studied population—not proof of every possible long-term outcome.

Before VERIFY, the randomized-withdrawal REVIVE study, published in the *New England Journal of Medicine* in 2024, had shown that rusfertide could maintain hematocrit control and reduce phlebotomy use in phlebotomy-dependent PV. Phase 3 confirmation was still essential: promising earlier research is not equivalent to approval-quality evidence. That progression is a useful case study in how new peptides are discovered and how candidates move beyond lists of promising peptides in clinical trials.

Administration, dose adjustment, and monitoring

Mimrylo is supplied as lyophilized powder in single-dose vials, co-packaged with diluent, and is administered subcutaneously. The FDA-labeled starting dose is 19 mg once weekly. The recommended weekly range is 9.5–108 mg, with increases considered only after at least two weeks at the current dose and guided by efficacy, safety, and the goal of keeping hematocrit below 45%. Doses above 54 mg require two injections; doses above 82 mg are divided between Day 1 and Day 4 or 5.

A healthcare professional should teach the patient or caregiver how to reconstitute and inject the medicine into the abdomen, thigh, or upper arm. The product is not a ready-to-inject research vial: preparation, inspection, storage after reconstitution, injection technique, and disposal are all governed by the approved Instructions for Use.

Dose reduction is specified for Grade 2 or worse anemia and for drug-related Grade 3 or worse toxicities. The label also gives different missed-dose instructions depending on whether the weekly amount is delivered once or split across two days. Those details are a reason to use the current prescribing information rather than an online dosing summary.

• CBC monitoring: after starting Mimrylo and during dose modifications, the label directs complete blood counts every 2–4 weeks or as clinically indicated.
• Hematocrit-guided titration: dose changes are made to reduce or maintain hematocrit below 45%, balanced against anemia and other toxicity.
• Platelet response: rising platelet counts may require changes to cytoreductive therapy, Mimrylo dose modification, or discontinuation.
• Ongoing PV care: the pivotal trial added Mimrylo to existing care; patients should not independently stop phlebotomy, aspirin, or cytoreductive therapy.

Safety findings and label warnings

During VERIFY's randomized 32-week period, the most common adverse reactions in the Mimrylo arm were injection-site reactions (56%) and anemia (16%). In the label's comparison table, thrombocytosis and dyspnea each occurred in 8% of Mimrylo recipients, versus 0.7% and 1.4%, respectively, with placebo. Trial rates describe the studied groups and period; they do not predict an individual's experience.

The warning for new or worsening thrombocytosis is especially relevant in a disorder already associated with abnormal blood counts. Within four weeks after starting Mimrylo, platelet counts increased by an average of 31% from baseline in the label dataset. The prescribing information reports thresholds and discontinuations, but the practical message is simpler: platelet counts must be followed and interpreted by the treating team rather than viewed in isolation.

Injection-site reactions reported across Mimrylo exposure in VERIFY were most often erythema, itching, pain, and swelling; nearly all were Grade 1 or 2. The label suggests symptomatic measures when needed. Anemia is mechanistically plausible when iron availability to erythropoiesis is restricted and was the most frequent reason for dose reduction.

Based on animal data, Mimrylo may cause fetal harm. The label recommends pregnancy testing before treatment for females of reproductive potential, effective contraception during treatment and for at least 30 days after the final dose, and stopping the drug if pregnancy occurs. Breastfeeding is not recommended during treatment and for at least 30 days after the final dose. There are no labeled contraindications, but 'none' does not mean no risks or no need for clinical judgment.

Why this peptide platform and approval matter

Rusfertide illustrates a core strength of therapeutic peptides: they can reproduce a biologically specific protein interaction that may be difficult to capture with a conventional small molecule. Protagonist discovered rusfertide through its peptide technology platform and led development through Phase 3; Takeda holds exclusive global development and commercialization rights. The finished medicine is a chemically defined cyclic peptide, not extracted human hormone.

Its target also broadens the peptide-development story. Ferroportin is a transmembrane solute transporter, and rusfertide acts by mimicking an endogenous regulatory hormone at that target. This is distinct from familiar metabolic peptide agonists and shows that peptide engineering can be used to modulate nutrient traffic as a therapeutic control point. The cyclic structure, lipid modification, and weekly subcutaneous regimen reflect the formulation and exposure engineering needed to turn a short natural signal into a practical medicine.

Regulatorily, first-in-class status means a new mechanism has cleared the FDA's standards for quality, safety, and substantial evidence of effectiveness for a defined indication. It does not establish that every hepcidin mimetic will work, that all synthetic peptides are interchangeable, or that unapproved rusfertide material is suitable for human use. The approval belongs to Mimrylo under its manufacturing controls, label, and postmarket safety system.

Scientifically, the next questions include how durable control and tolerability look with longer exposure, how clinicians integrate the drug across different PV risk groups and background regimens, and whether reduced phlebotomy burden translates into broader long-term outcomes. Approval begins real-world use and pharmacovigilance; it does not end evidence generation.